CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
sorafenib tosylate +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00330421
NCT00330421Phase 2Completed

A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma

National Cancer Institute (NCI)·interventional·Posted May 26, 2006·Updated Apr 30, 2014

In Brief

A Phase 2 clinical trial evaluating sorafenib tosylate, therapeutic conventional surgery, and 4 other interventions for Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor and 8 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This phase II trial is studying how well sorafenib works in treating patients with soft tissue sarcoma. Sorafenib may stop the growth of soft tissue sarcoma by blocking blood flow to the tumor and blocking some of the enzymes needed for tumor cell growth

Study Details

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2007
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.1 years ago

Interventions

sorafenib tosylatedrug

Given PO

therapeutic conventional surgeryprocedure

Undergo surgery

laboratory biomarker analysisother

Correlative studies

pharmacological studyother

Correlative studies

computed tomographyprocedure

Correlative studies

dynamic contrast-enhanced magnetic resonance imagingprocedure

Correlative studies